Related Experiment Video
Updated: May 3, 2026
09:58
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 14, 2010
22.3K
Dupilumab in persistent asthma with elevated eosinophil levels.
Sally Wenzel1, Linda Ford, David Pearlman
1Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. wenzelse@upmc.edu
The New England Journal of Medicine
|May 22, 2013
Summary
Dupilumab significantly reduced asthma exacerbations in patients with moderate-to-severe asthma and high eosinophil counts. This interleukin-4 receptor antagonist improved lung function and inflammatory markers during inhaled corticosteroid and long-acting beta-agonist withdrawal.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Moderate-to-severe asthma often presents challenges in effective treatment.
- Elevated eosinophil levels are a hallmark of certain severe asthma phenotypes.
- Interleukin-4 receptor alpha (IL-4Rα) signaling plays a key role in type 2 helper T-cell (Th2) mediated inflammation in asthma.
Purpose of the Study:
- To evaluate the efficacy and safety of dupilumab, an IL-4Rα antagonist, in patients with persistent, moderate-to-severe asthma.
- To assess dupilumab's impact on asthma exacerbations during a treatment withdrawal period.
- To investigate the effects of dupilumab on Th2-associated biomarkers and asthma control measures.
Main Methods:
- A randomized, placebo-controlled trial involving 104 patients with moderate-to-severe asthma and elevated eosinophils.
- Patients received weekly subcutaneous dupilumab (300 mg) or placebo.
- A protocol involved tapering and discontinuing inhaled glucocorticoids and long-acting beta-agonists (LABAs) during the study period.
Main Results:
- Dupilumab treatment resulted in an 87% reduction in asthma exacerbations compared to placebo (6% vs. 44%).
- Significant improvements were observed in lung function and asthma control metrics.
- Dupilumab effectively reduced Th2-driven inflammatory biomarkers.
Conclusions:
- Dupilumab therapy is associated with a significant reduction in asthma exacerbations in patients with eosinophilic asthma undergoing inhaled corticosteroid and LABA withdrawal.
- The treatment demonstrated improvements in lung function and key inflammatory markers.
- Dupilumab offers a promising therapeutic option for a specific phenotype of severe asthma.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
01:26Asthma-II: Pathophysiology and Classification
4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:28Asthma I: Introduction
112
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
112
01:13Asthma III: Clinical Manifestations
49
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
49